Skip to main content
Top
Published in: Critical Care 1/2004

01-02-2004 | Poster presentation

Use of national guidelines for the introduction of Drotrecogin alfa (activated)

Authors: S Mackenzie, L Patterson, L Plenderleith, F MacKirdy

Published in: Critical Care | Special Issue 1/2004

Login to get access

Excerpt

The Scottish Medicines Consortium approved the use of Drotrecogin alfa (activated) (Xigris©) in October 2002 and recommended that a register of patients receiving the drug be kept. The Scottish Intensive Care Society (SICS) developed guidelines for the use of this innovative therapy, suggesting that patients should have three or more of the systemic inflammatory response syndrome (SIRS) criteria in the presence of infection, at least two acute organ failures and an APACHE score of at least 25 [1]. …
Metadata
Title
Use of national guidelines for the introduction of Drotrecogin alfa (activated)
Authors
S Mackenzie
L Patterson
L Plenderleith
F MacKirdy
Publication date
01-02-2004
Publisher
BioMed Central
Published in
Critical Care / Issue Special Issue 1/2004
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc2588

Other articles of this Special Issue 1/2004

Critical Care 1/2004 Go to the issue